Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance

Molecular Genetics of Relapsed Diffuse Large B-Cell Lymphoma: Insight into Mechanisms of Therapy Resistance

The majority of patients with diffuse large B-cell lymphoma (DLBCL) can be treated successfully with a combination of chemotherapy and the monoclonal anti-CD20 antibody rituximab. Nonetheless, approximately one-third of the patients with DLBCL still experience relapse or refractory (R/R) disease aft...

Full description

Bibliographic Details
Main Authors: Madeleine R. Berendsen, Wendy B. C. Stevens, Michiel van den Brand, J. Han van Krieken, Blanca Scheijen
Format: Article
Language:English
Published: MDPI AG 2020-11-01
Series:Cancers
Subjects:
diffuse large B-cell lymphoma
relapse
therapy resistance
mutational analysis
Online Access:https://www.mdpi.com/2072-6694/12/12/3553

Internet

https://www.mdpi.com/2072-6694/12/12/3553

Similar Items